Previous close | 12.72 |
Open | 12.67 |
Bid | 12.53 x 800 |
Ask | 13.75 x 800 |
Day's range | 12.53 - 13.41 |
52-week range | 8.92 - 26.89 |
Volume | |
Avg. volume | 550,520 |
Market cap | 597.33M |
Beta (5Y monthly) | 1.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene therapy (CGT) and broader biopharma markets, today announced financial results for the third quarter and nine months of 2023.
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter financial results will be released after market close on Thursday, November 9, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business upda
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced Roderick de Greef has been appointed as Chairman of the Board of Directors and Chief Executive Officer replacing Michael Rice who is retiring after a seventeen year tenure, effective immediately. Rice has agreed to consult for the Company until March 31, 2024, to support a smooth transition.